Business Description
Centessa Pharmaceuticals PLC
ISIN : US1523091007
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.03 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | -0.51 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.62 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -128.1 | |||||
3-Year EPS without NRI Growth Rate | -118.7 | |||||
3-Year FCF Growth Rate | -123.2 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.92 | |||||
9-Day RSI | 43.52 | |||||
14-Day RSI | 43.28 | |||||
6-1 Month Momentum % | 75.86 | |||||
12-1 Month Momentum % | 144.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8 | |||||
Quick Ratio | 8 | |||||
Cash Ratio | 6.51 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -1.23 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2499.39 | |||||
Net Margin % | -2204.66 | |||||
FCF Margin % | -2371.36 | |||||
ROE % | -53.89 | |||||
ROA % | -38.18 | |||||
ROIC % | -326.22 | |||||
ROC (Joel Greenblatt) % | -1529.86 | |||||
ROCE % | -46.11 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 136.43 | |||||
PB Ratio | 3.99 | |||||
Price-to-Tangible-Book | 3.99 | |||||
EV-to-EBIT | -5.38 | |||||
EV-to-EBITDA | -5.41 | |||||
EV-to-Revenue | 130.51 | |||||
EV-to-FCF | -5.54 | |||||
Price-to-Net-Current-Asset-Value | 4.94 | |||||
Price-to-Net-Cash | 7.13 | |||||
Earnings Yield (Greenblatt) % | -18.58 | |||||
FCF Yield % | -15.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Centessa Pharmaceuticals PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 6.284 | ||
EPS (TTM) (€) | -1.449 | ||
Beta | 1.25 | ||
Volatility % | 61.68 | ||
14-Day RSI | 43.28 | ||
14-Day ATR (€) | 0.274504 | ||
20-Day SMA (€) | 9.0975 | ||
12-1 Month Momentum % | 144.02 | ||
52-Week Range (€) | 3.86 - 11.3 | ||
Shares Outstanding (Mil) | 111.66 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Centessa Pharmaceuticals PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Centessa Pharmaceuticals PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Centessa Pharmaceuticals PLC Frequently Asked Questions
What is Centessa Pharmaceuticals PLC(STU:260)'s stock price today?
When is next earnings date of Centessa Pharmaceuticals PLC(STU:260)?
Does Centessa Pharmaceuticals PLC(STU:260) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |